Recently, scientists from the Lausanne Research Institute in the UK and cancer biologists at the University of Kent in the UK have launched a research collaboration and found that Miyabeacin, a chemical substance that can kill a variety of cancer cells in the willow tree, including those that are resistant to certain drugs cancer cell. This substance has inhibitory activity against neuroblastoma. Neuroblastoma is the most common solid tumor in children under five years of age. It is a common childhood cancer that is difficult to treat. Its overall survival rate is less than 50%. An important issue of this tumor is drug resistance, so it is necessary to develop new drugs with new modes of action, and Miyabeacin may provide a new application opportunity in this regard.
Structurally, it contains two groups of salicin, which makes it potentially anti-inflammatory and anticoagulant with a double dose. However, the research results indicate that Mi yabeacin has inhibitory activity on many cancer cell lines, including acquired drug-resistant cell lines, providing further data support for the dual pharmacological effects of willow. The research team tested the effect of Miyabeacin on a range of cancer cell lines. The initial cell survival rate was determined from a neuroblastoma cell line established from a stage 4 neuroblastoma patient.
In laboratory tests, the researchers also found it to be effective against several breast, larynx, and ovarian cancer cell lines. The head of the study, Professor Mike Beale of the Lausanne Institute, said that the active ingredient salicin in aspirin has strong pharmacological activity, but Miyabeacin may have stronger pharmacological properties. The next step is to expand the market-scale production of Miyabeacin from artificially cultivated willows and provide more raw materials for further medical testing.